10 Results

Sort by: Published date Updated Date Title ID Descending Ascending

Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors Application This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors. Key Benefits ST80... Published: 12/9/2025       Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee

Precision Protein Repair Platform for Missense Mutations Application This technology enables targeted chemical correction of missense mutations in proteins using a modular heterotrifunctional molecule platform. Key Benefits Restores protein function by chemically mimicking healthy amino acid side chains. Modular toolkit allows rapid customization for diverse protein targets. Validated across multiple... Published: 11/12/2025       Contributor(s): Monika Raj

Gene Editing for Head and Neck Cancer Treatment Application Method for delivering gene-editing therapeutic in head and neck cancers. Key Benefits CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene. Liquid nanoparticle encapsulation permitting in vivo delivery. Market Summary Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%... Published: 11/7/2025       Contributor(s): Yong Teng, Yamin Li

Anticancer Agent with N-Glycan Specificity Application An engineered protein for targeting disease-associated N-glycans. Key Benefits High affinity, pH insensitive, no cofactors required. Applications in anticancer and antiviral therapeutics and research. Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties. Market Summary Glycosylation involves post-translation... Published: 12/5/2025       Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak

Treatment for Dengue Virus (DENV) Infection Application Antiviral therapeutic for multiple Dengue virus serotypes. Key Benefits Targets conserved regions of DENV genomes, enabling efficacy across serotypes. Mitigates lethal infections with a single lipid nanoparticle (LNP) based dose in mice. Minimal off-target effects. Market Summary Despite 390+ million annual DENV infections, there... Published: 10/30/2025       Contributor(s): Philip Santangelo, Daryll Vanover, Chiara Zurla, Lorena Carvalho de Souza Chaves

Combinatorial Therapy for Preserving Muscle Mass During Weight Loss Application A combinatorial therapy to preserve muscle mass during semaglutide weight loss treatment. Key Benefits Preserves lean mass during semaglutide treatment in preclinical mouse models. Increases overall fat loss without affecting food/water intake during semaglutide treatment in preclinical mouse models. Market Summary The prevalence... Published: 12/5/2025       Contributor(s): Todd Golde, Yong Ran, Eric Krause, Annette De Kloet, Karen Scott

Human Brain Proteins with Evidence Consistent with Causality of Alzheimer’s and Depression Application Research and therapeutic targets for Alzheimer’s disease, depression, and other neurological conditions mediated by protein expression in the brain. Key Benefits These findings can be utilized as a research tool to better understand the genetic basis of Alzheimer’s disease. Can also be utilized to develop therapeutics for... Published: 11/3/2025       Contributor(s): Aliza Wingo, Thomas Wingo, Yue Liu, Allan Levey, Nicholas (Nick) Seyfried, Duc Duong

KRAS Mutant Protein-Protein Interaction Targets and Inhibitors for Cancer Therapy Application Immunotherapeutic agent and biosensor for KRASG12V mutation in tumor cells. Key Benefits First in class, targeted immunotherapy for patients presented with KRASG12V mutation. Attenuates immune suppression associated with KRASG12V-positive cancers. Market Summary The KRASG12V mutation, representing 85% of all cancer mutations, is... Published: 10/15/2025       Contributor(s): Haian Fu, Cong Tang, Xiulei Mo

Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody... Published: 10/15/2025       Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai

Mitogenic Oxygenase Regulators for Drug Discovery Applications Can be used as a target for drug discovery, gene therapy and, to create a diagnostic tool. These applications are relevant to conditions involving inappropriate cell proliferation (e.g., cancer, atherosclerosis), angiogenesis, and tissue damage associated with inflammatory diseases. Technical Summary Reactive oxygen species (ROS) include... Published: 10/15/2025       Contributor(s): John David Lambeth, Guang Cheng